News Related to Eosinophilic Esophagitis

Related coverage linked through entity extraction aliases.

Dupilumab Phase 2 Trial Shows Significant Improvements for Eosinophilic Gastritis

Jun 29, 2026

A phase 2 clinical trial published in The Lancet Gastroenterology & Hepatology found that dupilumab significantly improved symptoms and biological markers in patients with eosinophilic gastritis, a rare stomach disease with no approved treatments. The DEGAS study involved 41 patients across 11 U.S. centers.

Kymera Presents Phase 1 KT-621 Data in Japanese Adults, Notes Ongoing Phase 2b Trials

Jun 12, 2026

Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.